Phase of Development: In Vivo Proof of Concept
Mechanism of Action: Neuroinflammation
Compound Type/Modality: Small Molecule
Targeting CNS LDLR to ameliorate tau-mediated neurodegeneration
David Holtzman, MD
Washington University (St. Louis, MO)
Andrew B. & Gretchen P. Jones Professor of Neurology and Developmental Biology
For further information about this program Contact:
-
Project Lead
Drug Discovery drugdiscovery@rainwatercf.org